Global patterns in monthly activity of influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus: a systematic analysis.


Journal

The Lancet. Global health
ISSN: 2214-109X
Titre abrégé: Lancet Glob Health
Pays: England
ID NLM: 101613665

Informations de publication

Date de publication:
08 2019
Historique:
received: 06 12 2018
revised: 16 04 2019
accepted: 30 04 2019
entrez: 16 7 2019
pubmed: 16 7 2019
medline: 23 5 2020
Statut: ppublish

Résumé

Influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus are the most common viruses associated with acute lower respiratory infections in young children (<5 years) and older people (≥65 years). A global report of the monthly activity of these viruses is needed to inform public health strategies and programmes for their control. In this systematic analysis, we compiled data from a systematic literature review of studies published between Jan 1, 2000, and Dec 31, 2017; online datasets; and unpublished research data. Studies were eligible for inclusion if they reported laboratory-confirmed incidence data of human infection of influenza virus, respiratory syncytial virus, parainfluenza virus, or metapneumovirus, or a combination of these, for at least 12 consecutive months (or 52 weeks equivalent); stable testing practice throughout all years reported; virus results among residents in well-defined geographical locations; and aggregated virus results at least on a monthly basis. Data were extracted through a three-stage process, from which we calculated monthly annual average percentage (AAP) as the relative strength of virus activity. We defined duration of epidemics as the minimum number of months to account for 75% of annual positive samples, with each component month defined as an epidemic month. Furthermore, we modelled monthly AAP of influenza virus and respiratory syncytial virus using site-specific temperature and relative humidity for the prediction of local average epidemic months. We also predicted global epidemic months of influenza virus and respiratory syncytial virus on a 5° by 5° grid. The systematic review in this study is registered with PROSPERO, number CRD42018091628. We initally identified 37 335 eligible studies. Of 21 065 studies remaining after exclusion of duplicates, 1081 full-text articles were assessed for eligibility, of which 185 were identified as eligible. We included 246 sites for influenza virus, 183 sites for respiratory syncytial virus, 83 sites for parainfluenza virus, and 65 sites for metapneumovirus. Influenza virus had clear seasonal epidemics in winter months in most temperate sites but timing of epidemics was more variable and less seasonal with decreasing distance from the equator. Unlike influenza virus, respiratory syncytial virus had clear seasonal epidemics in both temperate and tropical regions, starting in late summer months in the tropics of each hemisphere, reaching most temperate sites in winter months. In most temperate sites, influenza virus epidemics occurred later than respiratory syncytial virus (by 0·3 months [95% CI -0·3 to 0·9]) while no clear temporal order was observed in the tropics. Parainfluenza virus epidemics were found mostly in spring and early summer months in each hemisphere. Metapneumovirus epidemics occurred in late winter and spring in most temperate sites but the timing of epidemics was more diverse in the tropics. Influenza virus epidemics had shorter duration (3·8 months [3·6 to 4·0]) in temperate sites and longer duration (5·2 months [4·9 to 5·5]) in the tropics. Duration of epidemics was similar across all sites for respiratory syncytial virus (4·6 months [4·3 to 4·8]), as it was for metapneumovirus (4·8 months [4·4 to 5·1]). By comparison, parainfluenza virus had longer duration of epidemics (6·3 months [6·0 to 6·7]). Our model had good predictability in the average epidemic months of influenza virus in temperate regions and respiratory syncytial virus in both temperate and tropical regions. Through leave-one-out cross validation, the overall prediction error in the onset of epidemics was within 1 month (influenza virus -0·2 months [-0·6 to 0·1]; respiratory syncytial virus 0·1 months [-0·2 to 0·4]). This study is the first to provide global representations of month-by-month activity of influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus. Our model is helpful in predicting the local onset month of influenza virus and respiratory syncytial virus epidemics. The seasonality information has important implications for health services planning, the timing of respiratory syncytial virus passive prophylaxis, and the strategy of influenza virus and future respiratory syncytial virus vaccination. European Union Innovative Medicines Initiative Respiratory Syncytial Virus Consortium in Europe (RESCEU).

Sections du résumé

BACKGROUND
Influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus are the most common viruses associated with acute lower respiratory infections in young children (<5 years) and older people (≥65 years). A global report of the monthly activity of these viruses is needed to inform public health strategies and programmes for their control.
METHODS
In this systematic analysis, we compiled data from a systematic literature review of studies published between Jan 1, 2000, and Dec 31, 2017; online datasets; and unpublished research data. Studies were eligible for inclusion if they reported laboratory-confirmed incidence data of human infection of influenza virus, respiratory syncytial virus, parainfluenza virus, or metapneumovirus, or a combination of these, for at least 12 consecutive months (or 52 weeks equivalent); stable testing practice throughout all years reported; virus results among residents in well-defined geographical locations; and aggregated virus results at least on a monthly basis. Data were extracted through a three-stage process, from which we calculated monthly annual average percentage (AAP) as the relative strength of virus activity. We defined duration of epidemics as the minimum number of months to account for 75% of annual positive samples, with each component month defined as an epidemic month. Furthermore, we modelled monthly AAP of influenza virus and respiratory syncytial virus using site-specific temperature and relative humidity for the prediction of local average epidemic months. We also predicted global epidemic months of influenza virus and respiratory syncytial virus on a 5° by 5° grid. The systematic review in this study is registered with PROSPERO, number CRD42018091628.
FINDINGS
We initally identified 37 335 eligible studies. Of 21 065 studies remaining after exclusion of duplicates, 1081 full-text articles were assessed for eligibility, of which 185 were identified as eligible. We included 246 sites for influenza virus, 183 sites for respiratory syncytial virus, 83 sites for parainfluenza virus, and 65 sites for metapneumovirus. Influenza virus had clear seasonal epidemics in winter months in most temperate sites but timing of epidemics was more variable and less seasonal with decreasing distance from the equator. Unlike influenza virus, respiratory syncytial virus had clear seasonal epidemics in both temperate and tropical regions, starting in late summer months in the tropics of each hemisphere, reaching most temperate sites in winter months. In most temperate sites, influenza virus epidemics occurred later than respiratory syncytial virus (by 0·3 months [95% CI -0·3 to 0·9]) while no clear temporal order was observed in the tropics. Parainfluenza virus epidemics were found mostly in spring and early summer months in each hemisphere. Metapneumovirus epidemics occurred in late winter and spring in most temperate sites but the timing of epidemics was more diverse in the tropics. Influenza virus epidemics had shorter duration (3·8 months [3·6 to 4·0]) in temperate sites and longer duration (5·2 months [4·9 to 5·5]) in the tropics. Duration of epidemics was similar across all sites for respiratory syncytial virus (4·6 months [4·3 to 4·8]), as it was for metapneumovirus (4·8 months [4·4 to 5·1]). By comparison, parainfluenza virus had longer duration of epidemics (6·3 months [6·0 to 6·7]). Our model had good predictability in the average epidemic months of influenza virus in temperate regions and respiratory syncytial virus in both temperate and tropical regions. Through leave-one-out cross validation, the overall prediction error in the onset of epidemics was within 1 month (influenza virus -0·2 months [-0·6 to 0·1]; respiratory syncytial virus 0·1 months [-0·2 to 0·4]).
INTERPRETATION
This study is the first to provide global representations of month-by-month activity of influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus. Our model is helpful in predicting the local onset month of influenza virus and respiratory syncytial virus epidemics. The seasonality information has important implications for health services planning, the timing of respiratory syncytial virus passive prophylaxis, and the strategy of influenza virus and future respiratory syncytial virus vaccination.
FUNDING
European Union Innovative Medicines Initiative Respiratory Syncytial Virus Consortium in Europe (RESCEU).

Identifiants

pubmed: 31303294
pii: S2214-109X(19)30264-5
doi: 10.1016/S2214-109X(19)30264-5
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1031-e1045

Subventions

Organisme : Wellcome Trust
ID : 102975
Pays : United Kingdom

Investigateurs

Sozinho Acacio (S)
Wladimir J Alonso (WJ)
Martin Antonio (M)
Guadalupe Ayora Talavera (G)
Darmaa Badarch (D)
Vicky L Baillie (VL)
Gisela Barrera-Badillo (G)
Godfrey Bigogo (G)
Shobha Broor (S)
Dana Bruden (D)
Philippe Buchy (P)
Peter Byass (P)
James Chipeta (J)
Wilfrido Clara (W)
Duc-Anh Dang (DA)
Carla Cecília de Freitas Lázaro Emediato (CC)
Menno de Jong (M)
José Alberto Díaz-Quiñonez (JA)
Lien Anh Ha Do (LAH)
Rodrigo A Fasce (RA)
Luzhao Feng (L)
Mark J Ferson (MJ)
Angela Gentile (A)
Bradford D Gessner (BD)
Doli Goswami (D)
Sophie Goyet (S)
Carlos G Grijalva (CG)
Natasha Halasa (N)
Orienka Hellferscee (O)
Danielle Hessong (D)
Nusrat Homaira (N)
Jorge Jara (J)
Kathleen Kahn (K)
Najwa Khuri-Bulos (N)
Karen L Kotloff (KL)
Claudio F Lanata (CF)
Olga Lopez (O)
Maria Renee Lopez Bolaños (MR)
Marilla G Lucero (MG)
Florencia Lucion (F)
Socorro P Lupisan (SP)
Shabir A Madhi (SA)
Omphile Mekgoe (O)
Cinta Moraleda (C)
Jocelyn Moyes (J)
Kim Mulholland (K)
Patrick K Munywoki (PK)
Fathima Naby (F)
Thanh Hung Nguyen (TH)
Mark P Nicol (MP)
D James Nokes (DJ)
Daniel E Noyola (DE)
Daisuke Onozuka (D)
Nandhini Palani (N)
Yong Poovorawan (Y)
Mustafizur Rahman (M)
Kaat Ramaekers (K)
Candice Romero (C)
Elizabeth P Schlaudecker (EP)
Brunhilde Schweiger (B)
Phil Seidenberg (P)
Eric A F Simoes (EAF)
Rosalyn Singleton (R)
Sujatha Sistla (S)
Katharine Sturm-Ramirez (K)
Nungruthai Suntronwong (N)
Agustinus Sutanto (A)
Milagritos D Tapia (MD)
Somsak Thamthitiwat (S)
Ilada Thongpan (I)
Gayani Tillekeratne (G)
Yeny O Tinoco (YO)
Florette K Treurnicht (FK)
Claudia Turner (C)
Paul Turner (P)
Rogier van Doorn (R)
Marc Van Ranst (M)
Benoit Visseaux (B)
Sunthareeya Waicharoen (S)
Jianwei Wang (J)
Lay-Myint Yoshida (LM)
Heather J Zar (HJ)

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Auteurs

You Li (Y)

Centre for Global Health Research, University of Edinburgh, Edinburgh, UK.

Rachel M Reeves (RM)

Centre for Global Health Research, University of Edinburgh, Edinburgh, UK.

Xin Wang (X)

Centre for Global Health Research, University of Edinburgh, Edinburgh, UK.

Quique Bassat (Q)

Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique; ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain.

W Abdullah Brooks (WA)

Department of International Health, International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh.

Cheryl Cohen (C)

Centre for Respiratory Disease and Meningitis, National Institute for Communicable Disease, Johannesburg, South Africa; School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

David P Moore (DP)

Department of Paediatrics and Child Health, Chris Hani Baragwanath Academic Hospital and Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand, Johannesburg, South Africa.

Marta Nunes (M)

Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand, Johannesburg, South Africa.

Barbara Rath (B)

Vienna Vaccine Safety Initiative, Berlin, Germany; School of Medicine, University of Nottingham, Nottingham, UK.

Harry Campbell (H)

Centre for Global Health Research, University of Edinburgh, Edinburgh, UK.

Harish Nair (H)

Centre for Global Health Research, University of Edinburgh, Edinburgh, UK. Electronic address: harish.nair@ed.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH